This review found fluoroquinolones to be comparable to β-lactam antibiotics for acute bacterial sinusitis. However, a tendency towards more adverse events in the fluoroquinolone patients was observed in the sensitivity analyses. Respiratory fluoroquinolones are not recommended for use as a first-line intervention, but may be appropriate in cases where β-lactam antibiotic treatment has failed. Despite the poor reporting of the methodology, the conclusions are probably reliable.
Authors' objectives
To review the effectiveness and safety of fluoroquinolones in comparison with β-lactam antibiotics for acute bacterial sinusitis.
Searching MEDLINE (July 1965 to March 2007 and, subsequently, Scopus and the Cochrane CENTRAL Register were searched; the search terms were reported. The bibliographies of retrieved articles were handsearched for relevant studies. Publications in English, French, German, Italian and Greek were eligible.
Study selection
Only randomised controlled trials were eligible for this review; the included studies comprised open-label, double-blind and investigator-blinded designs. The inclusion criteria specified that the eligible intervention was respiratory or nonrespiratory fluoroquinolones, and the comparator β-lactam antibiotics. The included studies compared a variety of these drugs against one another. The patients were not restricted by age or gender (mean age 41.1years; 62.6% female), but they had to have a diagnosis of acute bacterial sinusitis based on clinical criteria (detailed clinical definition provided in the paper). The outcomes were not pre-specified in this review, but included studies reported cure according to clinical criteria, change in symptoms and bacteriological success of treatment.
Two reviewers independently evaluated studies for inclusion.
Assessment of study quality
The included studies were assessed for validity on the basis of the following criteria: randomisation, allocation concealment, masking of the intervention, and the reporting of withdrawals, crossovers between study arms and violations of inclusion criteria.
The authors did not state how the validity assessment was carried out.
Data extraction
Data were extracted from the included studies as 'clinical success' odds ratios (ORs) and 95% confidence intervals (CIs), which combined clinical cure and a substantial improvement in symptoms in the intention-to-treat populations. Safety data were extracted as the total number of adverse events in patients who were assessed for these outcomes. Secondary outcome data were extracted as 'clinical success' in the clinically evaluable population and the bacteriologically evaluable populations.
Two reviewers extracted the data, with any differences being resolved by discussion among all authors.
Methods of synthesis
The authors used a Mantel-Haenszel fixed-effect model for meta-analysis and assessed heterogeneity with the χ 2 and I
